| |
 Savara is an inhalation drug development company developing next generation respiratory therapeutics utilizing its proprietary NanoCluster dry-powder formulation technology.
The aerosols are assembled directly from nanoparticles of an existing therapeutic and delivered via oral pulmonary or nasal routes using off-the-shelf dry powder inhalers.
The NanoCluster Technology offers a Novel Formulation Approach to Dry Powders.
Particle size is critical for pulmonary drug delivery, and the ability to obtain particle sizes in the range of 1-3 microns has the potential to improve the efficacy of existing and new drug therapies. Savara’s NanoCluster technology utilizes nanotechnology to formulate high performance inhalation powder without the need for novel excipients or carrier particles. Savara’s NanoClusters are modeled after naturally occurring aerosols, which are highly effective in reaching the peripheral lung. These aerodynamics enable high drug concentrations in specific regions of the lung, independent of the inhalation flow rate. Savara expects that NanoCluster’s unique features will enable products that are currently difficult or impossible to develop using conventional inhalation powders.
|
Benefits include:
- Improved lung deposition & deep lung access
- Improved dissolution/ bioavailability
- High drug:excipient ratio
- Tidal flow rate independent delivery
- Synergistic drug combinations
- Water-based room temperature chemistry
- Non-spray drying process
- Macro-molecule delivery
- Control of Mass Mean Aerodynamic Diameter
- >90% fine particle fraction attainable
- Absence of carrier particles
- Little to no excipients required
- Uses proven scalable manufacturing process
|
| |
|
|
|
|
